SCHEMBL18409333

SCHEMBL18409333

FC(F)(F)c1cccc(-c2nc(Cc3c[nH]c4ccccc34)oc2-c2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.52
RXRB P28702 2/20 0.52
RXRG P48443 2/20 0.52
PTPN1 P18031 6/20 0.47
PIM1 P11309 1/20 0.43
PIM3 Q86V86 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
CCKBR P32239 1/20 0.43
TDO2 P48775 1/20 0.43
GPR84 Q9NQS5 3/20 0.42
SSTR1 P30872 1/20 0.42
SSTR2 P30874 1/20 0.42
SSTR4 P31391 1/20 0.42
SSTR3 P32745 1/20 0.42
GOT1 P17174 1/20 0.42
TACR1 P25103 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409336 0.91 RXRA (0.56) RXRARXRBRXRGCCKBRTDO2
SCHEMBL18409723 0.89 RXRA (0.54) RXRARXRBRXRGPTPN1CCKBR
SCHEMBL18409337 0.86 GPR84 (0.47) PTPN1ALDH1A1RAB9AGPR84GOT1
SCHEMBL18409571 0.86 GPR84 (0.50) PTPN1ALDH1A1RAB9AGPR84
SCHEMBL18409682 0.84 PTPN1 (0.54) PTPN1ALDH1A1RAB9AGPR84
SCHEMBL18409575 0.84 PTPN1 (0.64) RXRARXRBRXRGPTPN1ALDH1A1
SCHEMBL18409339 0.84 HTR6 (0.52) RXRARXRBRXRGPTPN1ALDH1A1
SCHEMBL18409568 0.82 GPR84 (0.57) PTPN1ALDH1A1RAB9AGPR84
SCHEMBL18409675 0.81 GPR84 (0.53) RXRARXRBPTPN1GPR84
SCHEMBL18409724 0.81 PTPN1 (0.45) RXRARXRBRXRGPTPN1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 RXRA 172/4885RXRB 232/4885RXRG 144/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 RXRA 1247/4885RXRB 1153/4885RXRG 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.